BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 15070934)

  • 1. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
    De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
    Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
    Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
    Gillam MP; Middler S; Freed DJ; Molitch ME
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
    Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
    Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
    Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
    Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
    Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma.
    Colao A; Vitale G; Di Sarno A; Spiezia S; Guerra E; Ciccarelli A; Lombardi G
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2770-5. PubMed ID: 15181056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.